Reply and AWS Announce Multi-Year Strategic Collaboration to Advance Generative AI Innovations, Helping Customers Design, Develop, and Deploy Scalable and Secure AI Applications
25.3.2025 10:00:00 CET | Business Wire | Press Release
Reply, a global leader in systems integration and consulting, today announced a multi-year strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in Generative Artificial Intelligence (GenAI). This collaboration will enable businesses worldwide to harness the power of AI by leveraging advanced cloud infrastructure and AI-driven capabilities. Together, Reply, with its companies Data Reply and Storm Reply, and AWS aim to create vertical solutions that increase process efficiency and boost productivity, and build specialized GenAI offerings spanning various industries and use cases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325287170/en/
Reply provides solutions on AWS starting from digital transformation consultancy to managed services. The new collaboration will drive the development and application of Generative AI solutions across industries, leveraging AWS services and Reply’s AI expertise.
The collaboration builds on a long-standing relationship between Reply and AWS. Over the years, Reply has been at the forefront of AI innovation with AWS, achieving the AWS Machine Learning Competency in 2020, gaining preview access to Amazon Bedrock in 2023, and being one of the first companies worldwide to earn the AWSGenerative AI Competency in 2024.
“We are thrilled to expand our collaboration with AWS to explore the full potential of Generative AI,” said Filippo Rizzante, CTO at Reply. “Our combined efforts will merge advanced AWS technology with Reply’s AI expertise to deliver transformative solutions for our clients. This collaboration not only reflects our dedication to innovation but also our commitment to helping organizations stay ahead in a rapidly evolving digital landscape.”
With this collaboration, Reply will enable its customers to efficiently adopt AWS, embracing AI at scale with a secure and streamlined approach. The Reply’s companies, Data Reply and Storm Reply, will deploy the advanced AI and machine learning services of AWS, including Amazon SageMaker, Amazon Bedrock, and Amazon Q, to design, develop, and deploy scalable and secure Generative AI applications for diverse use cases, including software engineering optimization, hyper-personalized customer experiences, operational efficiency, intelligent cost optimization, AI-driven operations, and sales and marketing automation.
As part of the agreement, Data Reply and Storm Reply will gain access to specialized training and resources. This initiative will empower them to deliver tailored AI solutions for clients across markets, with a specific focus on Automotive, FSI and Energy.
Reply’s expertise in AI is exemplified through several solutions, addressing concrete business challenges across various domains, including knowledge management, software development, customer engagement, supply chain optimization, security, and social media management. These solutions leverage advanced GenAI Agentic capabilities to deliver valuable results, such as:
- enhancing decision-making processes by enabling AI systems to intelligently integrate and analyze data from multiple knowledge sources for deeper insights.
- optimizing enterprise operations by seamlessly integrating AI with core business systems, enabling automated data processing in areas such as human resources, finance, supply chain management, and customer service to improve efficiency and streamline workflows.
- advancing market intelligence with AI-driven solutions that autonomously gather, analyze, and synthesize real-time market data into actionable insights, enabling businesses to stay ahead in dynamic markets.
Reply’s expertise translates into practical use cases for customers worldwide. For example, Storm Reply has partnered with Audi to enhance internal documentation processes using a RAG-based AI chatbot, streamlining document management and retrieval while improving operational efficiency. Additionally, Il Sole 24 Ore, one of Italy’s leading publishing groups, collaborated with Storm Reply and AWS to transform its renowned "L’Esperto Risponde" service using Generative AI. This solution, powered by Amazon Bedrock, enables experts to interact seamlessly with a knowledge base of over 130,000 documents, automating draft responses while maintaining high accuracy and significantly reducing response times.
As part of its continuous effort to push the boundaries of AI, Reply is also developing GenAI solutions leveraging Anthropic's Claude models on AWS. Anthropic's Claude models provide safe and reliable outputs aligned with user prompts, avoiding harmful activities. These models are integrated into Amazon Bedrock for secure data access. By combining Anthropic's Claude powerful models, AWS’s secure infrastructure, and Reply’s AI expertise, customers can benefit from unprecedented value.
"We're excited to bring advanced AI technologies and cloud capabilities to our expanded relationship with Reply. Together, we look forward to providing customers with choice, flexibility, and security when building and scaling with generative AI on AWS," said Antonio Alonso Lopez, Director of Partner Management for EMEA at Amazon Web Services. "Reply's deep technical expertise will help customers swiftly and responsibly deploy AI-powered applications that drive business transformation and accelerate innovation across multiple industries."
The collaboration aligns with Reply’s mission to remain at the forefront of AI innovation and digital transformation. As an AWS Premier Consulting Partner, Reply’s companies specialized in AWS technologies – Airwalk Reply, Comsysto Reply, Concept Reply, Data Reply, Discovery Reply, Retail Reply, Sense Reply, and Storm Reply – continue to deliver customized solutions and services that leverage AWS technologies to address clients’ unique challenges and drive substantial business outcomes.
Visit the website for more information about Reply and AWS’s strategic collaboration and their commitment to advancing Generative AI.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specializes in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325287170/en/
Contacts
Media Contacts:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Irene Caia
i.caia@reply.com
Tel. +3902545761
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom